Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06993038 · ClinicalTrials.gov registry record · Phase 4
Adenosine vs Diltiazem for Treatment of SVT in the ED
A Phase 4 study of Supraventricular Tachycardia (SVT), sponsored by Anne E. Zepeski.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06993038 is a Phase 4 study of Supraventricular Tachycardia (SVT) that is actively recruiting participants, run by Anne E. Zepeski. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06993038, a Phase 4 study of Supraventricular Tachycardia (SVT), is actively recruiting participants, sponsored by Anne E. Zepeski.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.
Conditions Studied
Interventions
- DRUG adenosine
- DRUG diltiazem
Study Locations (1)
Iowa
- University of Iowa Health Care - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06993038
The ClinicalTrials.gov registry entry for NCT06993038 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anne E. Zepeski, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Supraventricular Tachycardia (SVT) appearing as the primary indexed condition, and to 2 interventions - of which adenosine is the first listed.
NCT06993038 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT06993038 about?
NCT06993038 is a clinical study titled "Adenosine vs Diltiazem for Treatment of SVT in the ED". This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.
What is the current status of trial NCT06993038?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-08-01. Estimated completion is 2026-12.
What conditions does trial NCT06993038 study?
This clinical trial studies the following conditions: Supraventricular Tachycardia (SVT).
What interventions are being tested in trial NCT06993038?
The interventions under investigation include: adenosine (DRUG), diltiazem (DRUG).
Who is sponsoring clinical trial NCT06993038?
This trial is sponsored by Anne E. Zepeski, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06993038 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Supraventricular Tachycardia (SVT)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.